Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma is a phase 2, interventional study registered as NCT05518903 by Mayo Clinic, with a registry enrolment figure of 130 participants, started 2022-11-15 and due to reach its primary completion in 2027-06-30. Interventions recorded: Computed Tomography; Gallium Ga 68 FAPi-46; Positron Emission Tomography. Conditions listed: Localized Pancreatic Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma; Stage 0 Pancreatic Cancer AJCC v8; Stage I Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8. Primary outcome: Diagnostic performance of fibroblast-activation-protein-inhibitors (FAPI) positron emission tomography (PET) for detection and quantification of cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDA); Relationship between 68Ga-FAPI-46 PET metrics in PDA; Relationship between . Sites: United States. No results are recorded here; the registry entry is the source.